おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Cleveland BioLabs
company
About
Cleveland BioLabs is a clinical-stage biotech developing a robust pipeline of drugs for multiple medical and defense applications.
- 51 - 100
Highlights
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $10M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2003
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Cleveland BioLabs is a clinical-stage biotech developing a robust pipeline of drugs for multiple medical and defense applications, with a focus on oncology and tissue protection. The company pursues the research, development, and commercialization of proprietary products that have the potential to treat cancer, prevent, and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients.Cleveland BioLabs was established in 2003 and is headquartered in Buffalo, New York.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$10M
Cleveland BioLabs has raised a total of
$10M
in funding over 2 rounds. Their latest funding was raised on
Oct 1, 2013 from a Post-IPO Debt round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 1, 2013 | Post-IPO Debt | $10M | 1 |
Hercules Capital
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Cleveland BioLabs is funded by 1 investors.
Hercules Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
